Prognostic Impact of Claudin18.2 and TROP2 Expression in Advanced Gastric Cancer Treated With Nivolumab

Key Points

• This research aims to evaluate how claudin18.2 and TROP2 expressions affect survival outcomes in patients treated with nivolumab for advanced gastric cancer.
• Analysis of patient survival outcomes based on CPS scores and biomarker expression levels.
• Comparison of survival rates between CLDN18.2-positive and TROP2-positive patients.
• CPS ≥1 is linked to significantly longer survival in CLDN18.2-positive patients.
• TROP2-positive patients show a tendency towards improved overall survival with nivolumab.